CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The ORBIS project aims to enhance drug development efficiency by improving early-stage research and development processes. It brings together academia and industry to address challenges in drug solubility and permeability, ultimately aiming to increase the success rate of new drug candidates.
The current process of drug development is lengthy and inefficient.
Only 1 out of approximately 10,000 drug molecules enters the market.
Therefore more effective medicines, demanded by society, cannot be provided by pharmaceutical industry.
To fill this gap, Open Research Biopharmaceutical Internships Support (ORBIS) proposes that the high attrition rate of new drug candidates might be reduced by over 20% by improving early stage R&D productivity.
The overarching objective of ORBIS is therefore…
POZNAN UNIVERSITY OF MEDICAL SCIENCES
UNIWERSYTET MEDYCZNY IM KAROLA MARCINKOWSKIEGO W POZNANIU
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Ukraine, Kijev
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Ireland, Dublin
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
LUKASIEWICZ RESEARCH NETWORK - PHARMACEUTICAL RESEARCH INSTITUTE PRI
Poland, Warszawa
Type: Other
Activity type: Other
SME: No
Germany, Greifswald
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
